BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 – Evalstotug (CTLA-4 antibody) Phase 1 study progressing well, anticipate clearing doselimiting toxicity (DLT) observation period with 1 gram (14.2 mg/kg) in 2Q 2024 and initial Ph ...

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024. Presentation Details: Title:     Pha ...

BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Conference Call March 26, 2024 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Jay Short - Chairman, Chief Executive Officer and Co-Founder Richard Waldron - Chief Financial Officer Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Reni Benjamin - Citizens JMP Securities Operator Greetings and welcome ...

Financial Performance - The company reported net losses of $123.5 million and $106.5 million for the years ended December 31, 2023 and 2022, respectively, with an accumulated deficit of $416.3 million as of December 31, 2023[407]. - The company reported a net loss of $123.5 million for the year ended December 31, 2023, compared to a net loss of $106.5 million in 2022, indicating an increase in losses of approximately 15.5%[429][430]. - The net loss for 2023 was $123.5 million, compared to a net loss of $106.5 million in 2022, resulting in a net loss per share of $2.58[456]. - Total operating expenses for 2023 were $129.7 million, a 19.9% increase from $108.1 million in 2022, driven primarily by research and development expenses of $103.7 million[456]. - Total stockholders' equity decreased from $180.3 million in 2022 to $70.7 million in 2023, a decline of 60.8%[453]. Research and Development - Research and development expenses increased to $103.7 million in 2023 from $79.3 million in 2022, primarily driven by advancements in clinical-stage ADC programs and other pre-clinical programs[419]. - The increase in research and development expenses includes a $11.2 million rise for Phase 2 clinical-stage ADC programs and a $7.4 million increase for the CTLA4 immuno-oncology program[420]. - Research and development expenses accounted for approximately 80% of total operating expenses in 2023, underscoring the company's focus on product development[456]. - The company is advancing multiple clinical development programs, including mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182, which will require substantial additional capital[407]. - The company anticipates that its expenses and capital requirements will increase substantially as it advances its clinical development efforts[407]. Cash and Liquidity - As of December 31, 2023, cash and cash equivalents totaled approximately $111.5 million, expected to fund operations for at least twelve months[410]. - Cash used in operating activities was $104.0 million in 2023, up from $90.4 million in 2022, reflecting a year-over-year increase of 15.8%[429][430]. - Cash and cash equivalents at the end of 2023 were $111.5 million, down from $215.5 million at the end of 2022, indicating a significant decrease in liquidity[461]. - The company plans to fund its ongoing losses through public or private equity or debt financings, with a potential gross sales proceeds of up to $100 million from an Open Market Sale Agreement[466]. - The company expects to face challenges in raising additional capital due to market volatility and other economic factors[428]. Collaborations and Revenue - The company has entered into collaborations and licensing agreements that may provide future milestone and royalty payments, but did not recognize any revenue from these agreements in 2023 or 2022[412]. - The company has not recognized any revenue from the BeiGene collaboration for the years ended December 31, 2023, and 2022[536]. - The collaboration agreement with Bristol-Myers Squibb did not impact the Company's financial results for the years ended December 31, 2023, or 2022[537]. Assets and Liabilities - As of December 31, 2023, the company reported total assets of $119.7 million, a decrease of 46.9% from $225.7 million in 2022[452]. - Total current assets decreased from $220.4 million in 2022 to $116.4 million in 2023, a decline of 47%[452]. - Total liabilities increased from $45.4 million in 2022 to $49.0 million in 2023, an increase of 5.8%[453]. - The company's accumulated deficit increased to $416.3 million in 2023, up from $292.8 million in 2022, reflecting ongoing operational losses[453]. Stock and Equity - The total number of common stock options outstanding increased from 2,736,918 in 2022 to 6,273,507 in 2023[495]. - The total number of restricted stock units increased from 510,039 in 2022 to 99,104 in 2023[495]. - The total number of common shares authorized for issuance under the 2020 Equity Incentive Plan increased to 9,196,970 in 2023 from 7,658,509 in 2022, an increase of 20.1%[520]. - The total unrecognized stock-based compensation cost for unvested common stock options was $15.6 million, expected to be recognized over approximately 2.8 years[527]. - The Company issued 165,550 shares under the Employee Stock Purchase Plan (ESPP) in 2023, compared to 147,564 shares in 2022[531]. Tax and Deferred Assets - The Company had federal net operating loss carryforwards of approximately $119.2 million, which can be carried forward indefinitely, subject to an 80% limitation against taxable income[554]. - The Company established a valuation allowance of approximately $85.6 million as of December 31, 2023, to offset deferred tax assets, which increased by approximately $28.9 million during 2023[553]. - The Company had gross unrecognized tax benefits of approximately $3.6 million as of December 31, 2023, none of which would affect the effective tax rate due to the valuation allowance[559]. Operational Insights - The impact of the COVID-19 pandemic on the company's operations remains uncertain and will depend on future developments[411]. - The Company views its operations as a single operating segment, streamlining performance assessment[470]. - The Company has not entered into any off-balance sheet arrangements as defined by SEC rules and regulations[440]. - The Company has not experienced any losses in its cash accounts and believes it is not exposed to significant credit risk[473].

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 – CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 – CAB-AXL (BA3011) P ...

Financial Data and Key Metrics Changes - Cash and cash equivalents as of September 30, 2023, were $141.3 million, down from $215.5 million as of December 31, 2022, with expectations to fund operations into the second half of 2025 [20] - Research and development expenses for Q3 2023 were $28.4 million, an increase from $19.8 million in Q3 2022, primarily due to clinical product development expenses [20] - General and administrative expenses were $6.6 million for Q3 2023, slightly up from $6.3 million in Q3 2022 [21] - Net loss for Q3 2023 was $33.3 million, compared to a net loss of $25.8 million in Q3 2022 [21] Business Line Data and Key Metrics Changes - BA3011 Phase II study in non-small cell lung cancer showed an objective response rate of 27.8% among patients previously treated with PD-1 therapy [7] - In patients with EGFR wild-type, non-squamous lung cancer, 33.3% had a partial response to BA3011 monotherapy [7] - BA3021, a CAB-ROR2-ADC, completed enrollment of approximately 20 patients in both lung cancer and melanoma studies, with early responses observed [11] Market Data and Key Metrics Changes - AXL expression in lung cancer is associated with poor prognosis, with patients in the study having a median of three prior lines of therapy [8] - The company is exploring the potential clinical benefits of BA3011 in AXL TmPS negative patients, which could broaden market opportunities [8] Company Strategy and Development Direction - The company aims to form strategic collaborations with major pharmaceutical partners to accelerate the development of selected assets [6] - Focus remains on delivering innovative therapies to cancer patients with significant unmet medical needs, particularly through the CAB platform [10] Management's Comments on Operating Environment and Future Outlook - Management received verbal FDA feedback supportive of a registrational path for BA3011 in lung cancer, with formal written feedback expected soon [26] - The company believes that the CAB platform demonstrates compelling clinical efficacy and safety across multiple therapeutic targets [23] Other Important Information - Dr. Bin Zhang joined as Senior Vice President, Head of Clinical Development and Operations, bringing over 20 years of experience in oncology drug development [18] - An abstract on BA3011 was accepted for presentation at the IASLC conference in December [19] Q&A Session Summary Question: Feedback on registrational path for BA3011 - Management received clear and actionable items from the FDA regarding the registrational path and expects to communicate more details in December [26] Question: Details on IASLC conference presentation - A standard poster presentation will include data sets, including spider plots and swimmers plots, with updates on combination therapy and more frequent dosing data [28][29] Question: Competition in non-small cell lung cancer - Management noted that responses at low AXL expression levels hint at broader market opportunities, with ongoing evaluations of AXL negative patients [33][35] Question: Data sharing for non-small cell lung cancer - Management confirmed that data on non-small cell lung cancer will be shared at an upcoming meeting, with a focus on prioritizing AXL lung for that indication [37] Question: Enrollment status for bispecific candidate BA3182 - Enrollment is progressing well, with the study actively dosing and showing positive early results [43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

Financial Data and Key Metrics Changes - As of June 30, 2023, the company had $168.7 million in cash and cash equivalents, down from $215.5 million as of December 31, 2022, indicating a decrease in liquidity [18] - The net loss for the second quarter of 2023 was $35.8 million, compared to a net loss of $28.9 million in the same period of 2022, reflecting increased operational costs [19] - Research and development expenses rose to $31 million for Q2 2023, up from $20.7 million in Q2 2022, primarily due to intensified clinical development efforts [20] Business Line Data and Key Metrics Changes - The company is advancing BA-3011 in ongoing Phase II studies, including a potentially registrational study for UPS, with promising results in antitumor activity and safety profile [8][10] - BA-3021 is currently undergoing Phase II trials for four different indications, with ongoing patient enrollment and data collection expected in the second half of the year [12][14] Market Data and Key Metrics Changes - The company is focused on addressing significant unmet medical needs in oncology, particularly in solid tumors with high unmet needs, which presents substantial commercial opportunities [5][12] - The ongoing multicenter investigator-initiated Phase II clinical trial in platinum-resistant ovarian cancer is fully enrolled, with interim data readout expected in the second half of the year [12][14] Company Strategy and Development Direction - The company aims to advance commercial preparations in key global markets while exploring selective licensing opportunities to extend its cash runway [19] - The strategy includes leveraging its proprietary conditionally active biologics (CAB) platform to develop innovative therapies targeting various tumor types [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made with BA-3011 and BA-3021, highlighting the potential for these assets to address significant patient needs and create shareholder value [22] - The company remains on track to achieve key milestones by year-end, with a focus on clinical execution and data collection from ongoing trials [22] Other Important Information - The company has received FDA clearance for its dual CAB bispecific T-cell engager antibody, BA-3182, and is actively enrolling patients in a Phase I study [16] - The company plans to present data at upcoming medical meetings, showcasing progress in its clinical programs [17] Q&A Session Summary Question: Can you talk about the data provided to the FDA regarding the study design? - Management indicated that they approached the FDA with questions related to study design and provided updates on current data [26][27] Question: How many patient data do you expect to include in the follow-up? - Management anticipates a comprehensive analysis of patient data by the end of the year, which will inform future decisions [28][29] Question: What factors are considered when prioritizing indications for BA-3021? - Management stated that they evaluate the entire portfolio and consider safety and efficacy data when making prioritization decisions [31][32] Question: Any updates on clinical activity for the BA-3071 fifth cohort dosing? - Management expressed satisfaction with safety data and preliminary results, indicating ongoing analysis across multiple indications [35][36] Question: When do you expect to complete the frequent dosing study? - Management expects to have sufficient data for the frequent dosing study to inform the registrational study plan within the year [37][38] Question: Can you provide insights on the ovarian cancer study and data expectations? - Management indicated that the study is fully enrolled and they are looking forward to interim data, with a focus on response rates and overall survival [67]

jay and car UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation ...